Ofloxacin

Ofloxacin is a second-generation fluoroquinolone, a family of synthetic antibiotics derived from the older quinolone nalidixic acid and distinguished by a fluorine atom that broadens their antibacterial reach ^[1]. Chemically it is a racemate, an equal mixture of two mirror-image forms, only one of which is active; that active isomer was later developed and sold on its own as levofloxacin, which is several times more potent than the original racemic drug against many bacteria ^[2].

The compound was patented in 1980 and entered medical use in the mid-1980s, first appearing in Japan before gaining approval in the United States in 1990 ^[1]. It is included on the World Health Organization's List of Essential Medicines and is widely available as an inexpensive generic.

Ofloxacin has a broad spectrum, with activity against many Enterobacteriaceae, Pseudomonas aeruginosa, staphylococci and streptococci, as well as Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycobacterium tuberculosis ^[1]. This range has supported its use in lower respiratory tract infections, urinary tract infections and prostatitis, skin and soft tissue infections, pelvic inflammatory disease, and, as part of combination regimens, drug-resistant tuberculosis; fluoroquinolones including ofloxacin have also been used to treat enteric fever such as typhoid ^[1][4]. Topical forms are applied as eye drops for superficial eye infections and as ear drops for certain ear infections. An important caveat is that fluoroquinolone resistance can emerge rapidly, and ofloxacin is no longer recommended for gonorrhea because resistant strains became widespread ^[1].

Pharmacologically, ofloxacin is well absorbed when taken by mouth and is eliminated largely unchanged by the kidneys, and it is supplied as oral tablets, an intravenous solution, and topical eye and ear preparations ^[1]. It is a prescription medicine.

As a fluoroquinolone, ofloxacin carries the serious safety warnings characteristic of the class, and regulators have applied boxed warnings to these drugs. The most distinctive is a risk of tendon inflammation and rupture, classically of the Achilles tendon, which is more likely in older people and those taking corticosteroids and can occur even months after treatment ^[3]. Other recognized risks include potentially lasting peripheral nerve damage, central nervous system effects such as seizures, prolongation of the heart's QT interval, worsening of myasthenia gravis, and Clostridioides difficile associated diarrhea, considerations that have led guidelines to reserve fluoroquinolones for situations where other options are unsuitable ^[1][3].

Ofloxacin is prescription only and, like other fluoroquinolones, carries boxed warnings from regulators. It can cause tendon inflammation and rupture, especially in older adults, those on steroids, and transplant recipients; it may also worsen muscle weakness in myasthenia gravis and, rarely, cause lasting nerve damage or central nervous system effects such as confusion and seizures. It can prolong the heart's QT interval and cause photosensitivity, and it may trigger Clostridioides difficile diarrhea. It interacts with antacids, iron, calcium, and other minerals that block its absorption, and with drugs that also affect the QT interval. Given these risks, it is reserved for situations where the benefit clearly outweighs the harm.

The most reliable interaction is also the most avoidable. Polyvalent cations chelate the fluoroquinolone core, so aluminum and magnesium antacids, calcium, iron, zinc, sucralfate and buffered didanosine formulations bind ofloxacin in the gut and can cut absorption enough to make treatment fail.

Ofloxacin prolongs the QT interval, and that adds to class IA and class III antiarrhythmics, many antipsychotics, methadone and macrolides, with torsade de pointes the feared outcome; uncorrected hypokalemia from diuretics compounds it. Fluoroquinolones also weakly antagonize GABA-A signaling, and NSAIDs given alongside amplify that, producing tremor, agitation or frank seizures. Potentiation of warfarin with a rising INR has been reported, and glucose control can move in either direction with sulfonylureas and insulin. Systemic corticosteroids raise the risk of tendinopathy and tendon rupture.

Worth separating from its class: unlike enoxacin and ciprofloxacin, ofloxacin is a negligible inhibitor of CYP1A2 and has little effect on theophylline or caffeine clearance. Ofloxacin is cleared mostly unchanged by the kidney, which is why its metabolic interaction profile is quiet.

Checking a whole stack? Run it through interactions + stacks.

Ofloxacin is a second-generation fluoroquinolone antibiotic developed in Japan by Daiichi Seiyaku, emerging from the wave of quinolone research that followed nalidixic acid and built on the breakthrough of norfloxacin. It was first described in the early 1980s and introduced into clinical use later that decade, marketed under brand names including Floxin and, as ophthalmic and otic preparations, Ocuflox.

Chemically it is a racemic mixture, and researchers subsequently isolated its more active left-handed enantiomer, which was developed and marketed separately as levofloxacin. Over the following decades ofloxacin was applied broadly to respiratory, urinary, skin, and certain sexually transmitted infections, and it became a component of some multidrug-resistant tuberculosis regimens. Its clinical role has since narrowed as bacterial resistance spread and as class-wide safety warnings, notably regarding tendon injury, prompted more selective use.

Ofloxacin earned a solid reputation as a dependable broad-spectrum antibiotic during the era when fluoroquinolones transformed the oral treatment of serious bacterial infections. Its wide activity against both gram-positive and gram-negative organisms, good tissue penetration, and convenient dosing made it a workhorse for respiratory, urinary, and genital infections, and its eye and ear drops remain useful for local infections. It also holds a place in the history of drug design, since its active half lives on as the widely prescribed levofloxacin. In candor, its standing has diminished; resistance among key pathogens such as the gonococcus rose quickly, and the fluoroquinolone class as a whole now carries prominent warnings about uncommon but serious tendon, nerve, and other injuries, which has appropriately narrowed its use to situations where its benefits clearly outweigh those risks.